Founded in 2007 as a spin-off from the University of the Basque Country, the business sells from a catalogue of human and animal primary cells covering cardiac, dermal, hepatic, neural, ocular, pulmonary, renal and skeletal systems, alongside immortalized primary cells, nuclear receptor cell lines, PriGrow medium kits and TTFLUOR fluorescent cells. A proprietary GPCR screening technology underpins recombinant cell lines for dozens of receptor families, from adenosine and adrenergic through muscarinic, opioid and serotonin receptors, and is used to separate compounds with real efficacy from those carrying unwanted side-effect liabilities. The assay menu is grouped as target-based work on GPCRs and nuclear hormone receptors, organ-specific toxicity, and phenotypic studies covering cell behaviour, cell damage analysis and disease models. Acting as a contract research organization, it concentrates screening services on GPCRs, fibrosis and neurodegeneration, including Alzheimer's disease, Parkinson's disease and ALS. Products reach researchers through distributors in more than a dozen countries across Europe, Asia and North America.
Innoprot
Innoprot is a leading biotechnology company specializing in the development of innovative cell-based assays, high-content screening (HCS) technologies, and custom screening services for drug discovery. By offering advanced in vitro cellular models‚ particularly in neurobiology and oncology‚ Innoprot helps pharmaceutical companies accurately identify promising hits and evaluate drug efficacy early.
